thank Hi, today. everyone, you and for us joining
businesses a delivering consistently also establish double-digit as solid forward of track Diabetes note took another the return growth. growth international to continued step the particular strength across a this we U.S. record mid-single-digit in all and execution Pacing. Surgery, supported we organic Spine, markets expand quarter growth to Cardiac And in Heart momentum innovative with Cardiac had around as by we revenue we saw health Our growth strong care access Structural and globe. I'd our like the technologies Core multiple
like closed-loop same growth of differentially the had to pipeline products we've rapid systems. new approvals, way our advancing invest the tech time, approved, of product opportunities. with At highest tech. a and five into FDA bringing And and in we're robotics, in AI leading core technologies AI We're med cadence innovative the continuing we're already
comprehensive leveraging We execution, we're playing based also to and of the culture company. on to transformation efficiencies. speed make continue performance-driven on a scale our that's progress incorporating And win. to drive We're our
value So financials the cash we're when on our our in our you early opportunities high-return earnings converting strong And this quarter, you're return seeing to shareholders. restoring using earnings look invest to at and our of flow. both that into and power cash focus results
our to the exposure our So breakthrough we're strong years, over momentum, we growth coming executing to our And secular and our innovation, ongoing and the expect markets given we're transformation, catalysts our delivering. continue and across business. quarters numerous
mention Monitoring. and Interventions update of Respiratory line and comprehensive and our unprofitable we our Acute get retain our ventilator businesses have Patient business, one this portfolio to we're product After a decided calling into that QX do before on we our remaining results, and together bring PMRI exit which review, Now Care morning the I management provided details into to I a businesses. want Monitoring
of its long Now it's of stakeholders, shift both and vents profitability ACM market ventilators. the on near term Medtronic, interest best increasing business, because the and acuity it we've determined to to is preference in lower exit
the vents, strong of honoring legacy exit to we and serving our our business contracts. brand. the I customers of as ventilator And recognize Bennett the service we're Puritan and needs Now our want committed to
also business we role who ventilator them. And while the thank communities want customer production an pandemic new that can employees that the world in dramatically for get the believe existing we to ventilators during meet ventilators demand to I the going forward. our incredible around to to the expand manufacturers And played exit, needed do
time, and PMRI same refocus driven the remaining decision. retain at main the we have Now, to factors businesses. Three decided this
our in business First, properly we with position given and from and vents. have Acute our strong conviction Monitoring lead ability exiting and growth savings competitive Care drive to this improved in our fund
becoming Second, space this It's the this And differentiation. basis improves our is the fact in importance of innovation. of further rapidly. changing competitive data
lastly, high moves is more continue the going That deliver strategic but can growth. activity on both. a leadership forward, portfolio from broadly, and that And focus as mean prioritize and bar to innovation-driven will for we growth dilutes profit we away shy our company ACM and additional profitable category any not our does
we're increased these from using take investment and two bringing without vents decisions Acute creating Care provide savings you together, able the together, businesses dilution when P&L. to our Monitoring for to So all and
QX growth highest in our get quarter, all and line the let's leaders, businesses. algorithm. Now in into this market growth details three results synergistic Established In grew three behind categories:
contribution established digits, high businesses overall growth accelerate market synergistic our further and the in their grew quarters expect businesses to growth, mid-single single-digit while highest growth to leader and our we ahead. posted Our
grew at leaders. Combined, established revenue Now market looking first up half under made they just and our the of X%.
single-digit consistent Spinal of single-digit growth and delivered CST growth high systems, driving a Mazor imaging indicator AiBLE high adoption business. ecosystem. robotic enabling the in mid-teens in for future had double-digit StealthStation growth in Cranial Core in leading navigation, and biologics growth Spine, and We in on We're with unit our Starting above-market O-arm growth continued technology. this Technologies. growth strong
spine adaptive of intelligence, strong unit adoption our AI-based solution. We planning also integrated continue surgical to see
enabling robust with a for Now spine ecosystem of associated implants and surgeons. AiBLE, we're offering technologies complete
base, extensive over spine which Our rapidly and footprint, [ competitor. than industry. over global scale with ] systems increasing greater is Xx transforming includes the we're and this the installed nearest And XX,XXX
are We the way. leading
As integrated to and consolidation, and more is adopt our sales Medtronic technologies best where environment teams there spine to attracting from our business. we're disruption in expand surgeons grow an the
Next, in surgical, we grew X%.
wound sutures. management the our the Our barb on business, share, growing high in VLOC teens X strength of
And in permanent growth modest our We won also products impact had continue expected, ProGrip in synthetic from surgical surgery. hernia to as we have solid mid-single-digit bariatric with declines as growth in mesh platform. our share a
impact treatment to more more and seek permanent weight a as Now patients we be patients for surgery, temporary loss. believe will this still become as eligible
established cardiac our grew in cardiac up wrap rhythm To growth high X%, single-digit market leaders, also driven by pacing.
results, conduction growing an driven Our to pacemakers MicroAVX [ traditional of adoption system by chamber and to alternative single post continued alleles the pacing. our launch micro devices. We're VRX or pacing, from XX%, dual next-generation of strong the also ] benefiting
pacing, Our digits. grow XX-XX from only one lead, double conduction on the continue the to for approved -- system market
also CRM, Aurora ICD. our we began of limited training launch and In EV
Now we our reaccelerate expect the quarters. the EV in ICD, growth coming defibrillation to solutions
implant similar ICD with veins. one device leads benefits Aurora the of you changer a procedure. ICD size, pacing these As one harder the including and is benefits longevity, the in only without in I've game shared but It the and features, space. be the a realized And past, delivers in traditional with can
expect competitors the we population strong be for far expand advantages existing not and CRM. displace We device, growth the segment only will a our driver the will beyond
Now turning of grew mid-single and I'll the drivers some Combined, here. to highlight synergistic our businesses. they QX, digits in
grew grew on which competitor in quality aortic, markets Cardiac in of Surgery continued Avalos XX% with valve. Endurant perfusion start Let's our recovery strength strong international supply our momentum issues the surgical and and oxygenators driven cannula XX%, by of AAA and ECLS franchise. and sales given
rollout in our double-digit Coronary U.S. both Europe balloons. grew our guide And continued stent in increased fitters by Onex growth drug and drug-eluting on the stent. the share X%, we frontier driven in alluding of and
turning businesses growth our Now in to highest markets.
single earlier, I their in our these high and expect grew to this we forward. As accelerate quarter, to going contribution together, growth digits mentioned the businesses
quarter. the of global game-changing adoption Now Diabetes way, strong MiniMed our double prior XXX digits sequential growing growing We're system. the led the seeing over momentum, X% on
revenue growing Our driving customer more base customer. is sequentially, per we're and
driven only as intensive automatically adjust detection as delivers. outcomes AID highly sugars low these With users to insulin the attracting We nearly new In doubled proprietary every we correct insulin systems. as users flexible It the XXXG returned our features our X mid-single and competitor it U.S., XX% well in as pumps. targets year-over-year, offers differentiated. to choosing the technology. by growth are growth, injections revenue for digits, minutes. XXX grew matter. the And and of we meal daily It's those not Users multiple is on glucose system XXXG users, only outcomes
and of effort to control coming less leads burden. and And glycemic This is this users. high for time type with range
with SmartGuard technology. sensors And X from X Guardian pointing As among nearly third-party users that relief satisfaction. users, competitor It's our pump satisfaction. pump the of recent #X overall automation diabetes users, spending in sensor X,XXX worth Type out the survey a realize time that scored XXXG U.S. in in comes CGM our mirrored more in overall
has Simplera Sync XXXG, of this submit for in the Sync FDA our Mark size use the first Simplera Sync spring. Simplera the sensor. half It and release limited on. to the and during of half easier much quarter, a disposable sensor the with U.S., secured begin is design to with the look XXXG for current this the to we're And in the we calendar is year. CE planning put we our And to
for Diabetes pens, the to AID time. Now sensors is for an insulin smart even as to certainly we've management contribution acceleration ecosystem we're with using be And really technology dosing more good either There people in moves you, finished as from intensive through been turnaround some double-digit bring pumps, Diabetes work it diabetes Smart MDI, our I durable to driving robust we expect of including and we an not the work to next-generation patch differentiated growth to to or done business. smart got algorithms. space the living but growth, pumps, And here. more to feels definitely tell market return
Now We in growth turning solutions. including ablation international X% XX% markets, Western delivered in Europe. to growth cardiac
seeing, in PFA well strong continues pulse growth as ablation international still enthusiasm as the We're the a Front cryo leading stages. early lot Our for Arctic as of solution by products. our overall performance be our to market our in though, is driven
In cases. Europe, now and market offerings limited in shot, very we're have PFA segments. just shot seeing our started only And of in efficient procedures the single a PulseSelect for we're couple of system QX. single and here the the release focal And fiscal with after we both the company PFA
no really shaft French our noticeable muscle due to custom excellent curve been maneuverability is And small beneficial bidirectional The so patient reporting the XX are short. sheath. is its Clinicians for which has our handling with experience. and product, contraction learning also PFA catheter and
In system in to an focal, field It's only and the we continue frequency mapping limited ramp high-density ablation X both Sphere release and catheter. Sphere really and Europe. of market remain Affera is the pulse ablation radio that in perform can mapping. all-in-one and catheter catheter manufacturing X
in created and only had first In our cast faced space, the the quarter in competition a U.S., cryoablation declined been the the full the quarter. we which is player. of We business space
In PFA back they catheter, available. purchases launch now PulseSelect addition, which actually customers many is of the held awaited as commercially our
in European improve approved PFA commented catheter and to And the and paroxysmal both to how easily the FDA-approved it's we for connects recently nitron how their roll only do system. persistent visualized the cryo have from PulseSelect, addition consistently and mapping it well on expect clinicians out here AF. feedback, We console to as next-generation
system follow-up So patient mapping with in Affera our making Sphere per we're U.S. trial the in and progress catheter AF completed. also the pivotal last to our X now Sphere bringing
the We expect the first see calendar of medical a in year. meeting results to half the at
this size, space expanding in under-penetrated big cardiac ablation With an is a us. billion market opportunity $X share for our
growth who of expect this our patients towards need We first, and we pipeline innovation profile bring winning time, rich over technology. growth then as improve moving to to our market share
where China quarter, In when we in to exclude digits Neurovascular subject high single market you volume-based is the procurement. this grew sales
both in This globally. and driven diversion We pipeline technology have growth Flex innovative our double-digit diverters. being for continue treating on by aneurysms, flow flow Shield brain which Vantage available strong to is is
enrollment our in markets. EXPAND soon. to Surgical robotic pivotal Robotic Euro base hernia Hugo the continued first trial and our in In for In to enroll, we installed continues growing we trial system Technologies, international U.S., our expect have the differentiated very
digital and with open equipped advanced leading console us connected driver the training believe meaningfully our robotic instrumentation, Hugo, advance expect partnerships, low and a modular in our to meaningful and surgery our and of for the penetration ecosystem data-enabled capabilities, surgical world. digital We with years the surgeon invasive world-class minimally in surgery preference ahead. our for be around insights, position will design, We along growth program
We high performance. including Heart. see adoption Structural to we market-leading valve digits single of turning grew ongoing its sequentially digits FX, Now Evolut and quarter, in as the improved mid-single design
where we we plus easy FX the FX valve quarter, for coronary same have of windows the Japan XXs Plus that dependable the frame to Evolut Europe, full grew was share platform. providing performance news In the double today the continued grew submitted in low Evolut our adoption pleased to has approval. of to FDA three access And allow the FX while I'm on launched digits. for first the FX. in
will trial are trial on see as X. a also we be the our data results that pleased the late to as plus excited trial as as ACC business. at presented SMART continued our Structural were We're forward to hear X-year and Heart April of both And breaker results X-year having the our SMART to and catalysts well strength looking FX low-risk of for
that, raise. financial QX 'XX and our performance with fiscal deeper Karen? guidance let's look go Karen Now for at to a our
